TTOO Enterprise Value Over E B I T D A from 2010 to 2024

TTOO Stock  USD 0.39  0.06  14.33%   
T2 Biosystms Enterprise Value Over EBITDA yearly trend continues to be very stable with very little volatility. Enterprise Value Over EBITDA is likely to drop to -1.2. During the period from 2010 to 2024, T2 Biosystms Enterprise Value Over EBITDA quarterly data regression pattern had range of 729 and standard deviation of  282.55. View All Fundamentals
 
Enterprise Value Over EBITDA  
First Reported
2010-12-31
Previous Quarter
(1.14)
Current Value
(1.20)
Quarterly Volatility
282.54992818
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check T2 Biosystms financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among T2 Biosystms' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.1 M, Interest Expense of 4.9 M or Total Revenue of 9.8 M, as well as many indicators such as Price To Sales Ratio of 2.16, Dividend Yield of 0.0 or Days Sales Outstanding of 131. TTOO financial statements analysis is a perfect complement when working with T2 Biosystms Valuation or Volatility modules.
  
Check out the analysis of T2 Biosystms Correlation against competitors.
To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.

Latest T2 Biosystms' Enterprise Value Over E B I T D A Growth Pattern

Below is the plot of the Enterprise Value Over E B I T D A of T2 Biosystms over the last few years. It is T2 Biosystms' Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in T2 Biosystms' overall financial position and show how it may be relating to other accounts over time.
Enterprise Value Over E B I T D A10 Years Trend
Slightly volatile
   Enterprise Value Over E B I T D A   
       Timeline  

TTOO Enterprise Value Over E B I T D A Regression Statistics

Arithmetic Mean(214.12)
Coefficient Of Variation(131.96)
Mean Deviation221.58
Median(130.88)
Standard Deviation282.55
Sample Variance79,834
Range729
R-Value0.83
Mean Square Error27,086
R-Squared0.68
Significance0.0001
Slope52.29
Total Sum of Squares1.1M

TTOO Enterprise Value Over E B I T D A History

2024 -1.2
2023 -1.14
2022 -1.02
2021 -2.84
2020 -4.92
2019 -1.8
2018 -145.3

About T2 Biosystms Financial Statements

T2 Biosystms investors utilize fundamental indicators, such as Enterprise Value Over E B I T D A, to predict how TTOO Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Enterprise Value Over EBITDA(1.14)(1.20)
When determining whether T2 Biosystms offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of T2 Biosystms' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of T2 Biosystms Stock. Outlined below are crucial reports that will aid in making a well-informed decision on T2 Biosystms Stock:
Check out the analysis of T2 Biosystms Correlation against competitors.
To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.
You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of T2 Biosystms. If investors know TTOO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about T2 Biosystms listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.03)
Revenue Per Share
0.999
Quarterly Revenue Growth
(0.01)
Return On Assets
(0.90)
Return On Equity
(6.22)
The market value of T2 Biosystms is measured differently than its book value, which is the value of TTOO that is recorded on the company's balance sheet. Investors also form their own opinion of T2 Biosystms' value that differs from its market value or its book value, called intrinsic value, which is T2 Biosystms' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because T2 Biosystms' market value can be influenced by many factors that don't directly affect T2 Biosystms' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between T2 Biosystms' value and its price as these two are different measures arrived at by different means. Investors typically determine if T2 Biosystms is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, T2 Biosystms' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.